Depemokimab is associated with early and sustained improvements in patient-reported outcomes in CRSwNP: Data from the ANCHOR-1/2 trials
Bibliographic record
Abstract
Background: Depemokimab is the first ultra-long-acting biologic with enhanced IL-5 binding affinity, high potency and an extended half-life, enabling sustained suppression of type 2 inflammation and twice-yearly dosing. Aims: Investigate the earliest impact to patient-reported outcomes (PROs) with depemokimab in the integrated population of the Phase III ANCHOR-1/2 trials. Methods: Adults with inadequately controlled CRSwNP were randomised (1:1) to depemokimab (100 mg subcutaneous; n=272) or placebo (n=256), plus standard of care, once every 26 weeks for 52 weeks. Symptom-specific verbal response scales (VRS) for nasal obstruction and loss of smell (scale 0–3; higher scores indicate worse outcomes) were self-assessed daily and a mean weekly score was calculated per symptom. Results: Improvements in change from baseline in mean nasal obstruction VRS were observed by Week 3 with depemokimab (difference vs placebo [95% CI]: –0.15 [–0.29,–0.02], p=0.028) and by Week 4 for loss of smell VRS (–0.15 [–0.26,–0.03], p=0.012; both nominally significant). Improvements remained nominally significant at each timepoint until the end of the study (Week 52; Figure). Conclusions: Twice-yearly depemokimab provided early and sustained improvements in nasal obstruction and loss of smell, two cardinal and burdensome symptoms of severe CRSwNP. Funding: GSK (217095/218079; NCT05281523 /NCT05274750). erj;66/suppl_69/OA2335/F1 F1 F1
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.004 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.003 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.004 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".